Abstract: Objective To evaluate the effects of hemoperfusion (HP) for the treatment of hyperlipidemia and hypertriglyceridemia- induced acute pancreatitis (HTG- AP). Methods Twelve patients suffering from HTG-AP were retrospectively analyzed. They were treated with HP in addition to routine treatment. The improvement of hyperlipidemia, clinical symptoms, local and systemic complications, hospitalization days and mortality rate were analyzed. Results In the 12 patients at the time of admission, serum triglyceride (TG) was 54.542±19.019 mmol/L, and serum cholesterol (CHOL) was 13.158±5.242 mmol/L. After the first session of HP, serum TG reduced to 12.957±9.934 mmol/L (reduction rate of 77.740±11.668%, P＜0.001) and serum CHOL reduced to 8.294±6.960 mmol/L (reduction rate of 36.482±12.783%, P=0.016). Five of the 12 patients reached a TG level <10 mmol/L after two sessions of HP, and all of the patients had the serum TG level < 5.65 mmol/L within 1-3 days. The duration in ICU was 2.917±1.730 days, and hospitalization period was 11.500±8.939 days. None of them died. Conclusion HP can effectively reduce serum TG level and improve clinical outcomes in HTG-AP patients.

Key words: Hemoperfusion, Hypertriglyceridemia-induced acute pancreatitis, Serum triglyceride concentration, Therapeutic effect